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The calcium-sensing receptor (CaSR) is expressed in normal breast epithelial cells and in
breast cancer cells. During lactation, activation of the CaSR in mammary epithelial cells
increases calcium transport into milk and inhibits parathyroid hormone-related protein
(PTHrP) secretion into milk and into the circulation. The ability to sense changes in
extracellular calcium allows the lactating breast to actively participate in the regulation of
systemic calcium and bone metabolism, and to coordinate calcium usage with calcium
availability during milk production. Interestingly, as compared to normal breast cells, in
breast cancer cells, the regulation of PTHrP secretion by the CaSR becomes rewired
due to a switch in its G-protein usage such that activation of the CaSR increases
instead of decreases PTHrP production. In normal cells the CaSR couples to Gαi to
inhibit cAMP and PTHrP production, whereas in breast cancer cells, it couples to Gαs
to stimulate cAMP and PTHrP production. Activation of the CaSR on breast cancer cells
regulates breast cancer cell proliferation, death and migration, in part, by stimulating
PTHrP production. In this article, we discuss the biology of the CaSR in the normal breast
and in breast cancer, and review recent findings suggesting that the CaSR activates a
nuclear pathway of PTHrP action that stimulates cellular proliferation and inhibits cell
death, helping cancer cells adapt to elevated extracellular calcium levels. Understanding
the diverse actions mediated by the CaSR may help us better understand lactation
physiology, breast cancer progression and osteolytic bone metastases.
Keywords: calcium-sensing receptor, breast cancer, parathyroid hormone-related protein, mammary gland,
lactation
INTRODUCTION
The extracellular calcium-sensing receptor (CaSR) is a G-protein-coupled receptor (GPCR) that
was first identified because of its ability to regulate parathyroid hormone (PTH) secretion in
response to changes in extracellular free calcium (Ca2+) (Brown et al., 1993; Brown, 2013).
It belongs to class C of the GPCR superfamily, which also includes metabotropic glutamate
receptors (mGluRs), GABA B receptors, taste receptors and pheromone receptors (Pi et al., 2005;
Brauner-Osborne et al., 2007). The CaSR has been shown to bind and signal in response to
extracellular Ca2+ concentrations within the physiologic range (Brown and MacLeod, 2001). It
can also be activated by a variety of other cations and cationic compounds such as gadolinium,
amino acids, spermine and certain antibiotics (Brown and MacLeod, 2001; Ward et al., 2002).
The receptor appears to act as a homodimer, or perhaps a tetramer, and has also been
shown to heterodimerize to form hybrid, signaling complexes with other class C GPCRs (Bai
et al., 1998, 1999; Gama et al., 2001; Chang et al., 2007). The CaSR complex is sensitive to
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allosteric modulation that can alter its sensitivity to direct
agonists such as extracellular Ca2+, an aspect of its biology
that has been exploited to develop therapeutic agents such as
Cinacalcet (Brown and MacLeod, 2001; Filopanti et al., 2013).
The CaSR is highly expressed by parathyroid glands, bone
cells and the kidney where it acts to regulate PTH secretion,
bone turnover and renal calcium handling in order to coordinate
systemic calcium metabolism and to maintain a stable Ca2+
concentration in the extracellular fluid. In addition to its role
as a master regulator of calcium metabolism, a large body of
evidence also supports its involvement in the regulation of
diverse processes, such as cellular proliferation, differentiation,
apoptosis, hormone secretion, gene expression and ion transport
in many different organs (Brown and MacLeod, 2001; Hofer and
Brown, 2003; Brennan and Conigrave, 2009; Breitwieser, 2012;
Chakravarti et al., 2012; Brennan et al., 2013). Interestingly, at
sites other than the parathyroid gland, the CaSR often regulates
the secretion of parathyroid hormone-related protein (PTHrP)
(Wysolmerski, 2012), a locally produced cytokine growth factor
that is evolutionarily related to PTH and uses the same Type
1 PTH/PTHrP receptor (PTH1R). In this review we will focus
on the functions of the CaSR in mammary gland biology,
its regulation of mammary gland PTHrP production and its
contribution to the development and progression of breast
cancer.
THE CASR IN THE NORMAL BREAST
CaSR Expression in Normal Mammary
Epithelial Cells
The first documentation of CaSR expression in normal breast
tissue was reported by Cheng et al. (1998). They demonstrated
both CaSR mRNA and protein expression in ductal epithelial
cells in the human breast. Subsequent studies in mice confirmed
these observations and showed that CaSR mRNA levels in the
mouse mammary gland are low during ductal development and
early to mid-pregnancy but subsequently increase to a peak
during lactation (VanHouten et al., 2004). It is not entirely clear
whether these changes represent alterations in the proportion of
the gland represented by epithelial cells at these different time
points, an actual increase in the expression of CaSR mRNA in
individual epithelial cells, or both. Either way, the expression of
the CaSR is rapidly reduced after weaning of the pups and the
cessation of lactation. Cheng and colleagues demonstrated CaSR
staining on epithelial cells in human breast samples (Cheng et al.,
1998). Likewise, in mice, CaSR immunofluorescence staining
demonstrated that, during lactation, the receptor is expressed
primarily on the basolateral surface of ductal and alveolar cells
as well as within the intracellular compartment of these same
cells (VanHouten et al., 2004, 2007). Although these studies do
not rule out low levels of receptor in stromal cells, it appears that
the CaSR is located predominantly on epithelial cells within the
breast.
CaSR Function in the Normal Mammary
Gland
Our laboratory has disrupted the CaSR selectively in mammary
epithelial cells, using both MMTV-Cre and BLG-Cre mice.
In MMTV-Cre;CaSRlox/lox mice, the CaSR gene is disrupted
in mammary epithelial cells soon after weaning. This caused
no apparent abnormalities in ductal development during
puberty or alveolar development during pregnancy (Kim
et al., 2016). In contrast, in BLG-Cre;CaSRlox/lox mice, the
CaSR gene is disrupted in mammary epithelial cells at the
transition from pregnancy to lactation. While this did not
affect secretory differentiation of the epithelial cells, it did
have consequences for calcium transport, PTHrP production
and systemic calcium metabolism during lactation, confirming
previous pharmacologic and genetic studies (VanHouten et al.,
2004, 2007; Ardeshirpour et al., 2006; Mamillapalli et al., 2013).
These studies suggest that, despite its effects on proliferation and
apoptosis in breast cancer cells (see below), the CaSR does not
have a dominant role in regulating morphological development
or differentiation in the normal mammary gland. Therefore, we
will limit further discussion to the role of the CaSR in mammary
gland physiology during lactation.
Regulation of PTHrP Production
Parathyroid hormone-related protein (PTHrP, gene symbol
PTHLH) was discovered as the cause of humoral hypercalcemia
of malignancy (HHM) a common paraneoplastic syndrome
(Wysolmerski, 2012). It has important functions during
mammary gland development and also participates in the
regulation of systemic calcium metabolism during lactation.
PTHrP is produced by mammary epithelial cells and is secreted
both into milk and into the systemic circulation. Circulating
PTHrP activates bone resorption during lactation in order to
liberate maternal skeletal calcium stores that are used by the
mammary gland for milk production (Wysolmerski, 2012).
PTHrP in milk modulates neonatal calcium accrual through
unknownmechanisms (Mamillapalli et al., 2013). The expression
of Pthlh mRNA by the lactating murine mammary gland and
the secretion of PTHrP into the maternal circulation and into
milk are regulated by the CaSR so that PTHrP production
by mammary epithelial cells is ultimately responsive to the
availability of calcium for milk synthesis (VanHouten et al.,
2004; Ardeshirpour et al., 2006; VanHouten and Wysolmerski,
2007; Mamillapalli et al., 2013; VanHouten and Wysolmerski,
2013).
As noted in the Introduction, the CaSR has been shown
to regulate PTHrP production by several cell types, such as
astrocytes, ovarian epithelial cells, cytotrophoblasts, hepatocytes,
osteoblasts, prostate cancer cells, CaSR transfected HEK293
cells, and breast cancer cells (Brown and MacLeod, 2001;
Chattopadhyay, 2006; Reyes-Ibarra et al., 2007; Wysolmerski,
2012; Organista-Juarez et al., 2013). In most cell types studied,
activation of the CaSR stimulates PTHrP production. However,
in normal mammary epithelial cells, activation of the CaSR
suppresses PTHrP production (Sanders et al., 2000; VanHouten
et al., 2004). Our laboratory, as well as others, has demonstrated
this effect in the intact mammary gland as well as in isolated
mammary epithelial cells in cell culture using both genetic
and pharmacologic approaches. For example, reducing dietary
calcium intake in lactating wild-type mice increases Pthlh gene
transcription and PTHrP secretion into milk. Increasing dietary
calcium intake in lactating WT, PTH−/−, 1α(OH)ase+/− or
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1α(OH)ase−/− mice did the opposite and decreased PTHrP
concentrations, demonstrating a consistent inverse relationship
between circulating calcium concentrations and mammary
PTHrP levels in lactating mice (Cao et al., 2009; Ji et al.,
2011; VanHouten and Wysolmerski, 2013). Infusion of the
calcimimetic compound NPS-R467, an allosteric activator of the
CaSR, in lactating mice fed a low calcium diet recovered PTHrP
production to levels observed in control mice fed a normal
calcium diet, demonstrating that these dietary manipulations
regulate mammary PTHrP production through the CaSR
(VanHouten et al., 2004). We have also observed similar findings
in genetic models of CaSR deficiency. Homozygous disruption
of the CaSR gene results in neonatal death, but the mammary
glands of CaSR+/− mice produce more PTHrP during lactation
than WT mice (Ardeshirpour et al., 2006). To circumvent
the neonatal death of CaSR−/− mice, we used the BLG-Cre
transgene to disrupt the floxed Casr gene during late pregnancy
and lactation (Mamillapalli et al., 2013). Loss of the CaSR on
mammary epithelial cells resulted in increased Pthlh mRNA
expression, increased milk PTHrP levels and increased secretion
of PTHrP into the maternal circulation. All together, these
studies support the conclusion that activation of the CaSR
on mammary epithelial cells suppresses PTHrP production
and secretion into the circulation and milk (VanHouten
and Wysolmerski, 2013). As discussed below, this defines a
negative feedback loop between calcium delivery to the lactating
mammary gland and PTHrP production by mammary epithelial
cells.
The CaSR binds Ca2+ mainly through the large extracellular
domain (ECD) and acts as a homodimer or heterodimer (Bai
et al., 1998, 1999; Chakravarti et al., 2012). Upon ligand binding,
the CaSR undergoes a conformational change, which promotes
GDP dissociation from a Gα subunit of a heterotrimeric
G-protein complex, causing it to dissociate from the Gβγ
subunits. As with many GPCRs, the CaSR interacts with multiple
Gα sub-types, and the downstream signaling pathways are highly
divergent, and depend on the cellular context (Chakravarti et al.,
2012). The CaSR has been shown to stimulate the PLC/PKC
pathway downstream of Gαq and to decrease cAMP downstream
of Gαi (Chakravarti et al., 2012). Both Gαq and Gαi, as well as
interaction with the scaffolding proteins filamin-A and caveolin-
1, are thought to be involved in the inhibition of PTH secretion by
the CaSR in parathyroid chief cells (Chakravarti et al., 2012). In
several cell types, the CaSR has been suggested to regulate PTHrP
secretion by modulating MAPK signaling (Tfelt-Hansen et al.,
2003). However, in normal mammary epithelial cells, regulation
of cAMP/PKA pathways appears to be more important for
PTHrP production than changes in the MAPK/ERK pathway
(Mamillapalli et al., 2008). Our laboratory has demonstrated
that, in normal breast cells, the CaSR couples with Gαi to
decrease cAMP production by adenylylcyclase, and subsequently
PKA activation, without affecting phosphodiesterase activity
(Mamillapalli et al., 2008). Lower cAMP production results in
the inhibition of Pthlh gene expression and PTHrP secretion,
an effect that can be mimicked by inhibition of PKA, or
reversed with forskolin or dibutyryl-cAMP (Mamillapalli et al.,
2008).
Regulation of Calcium Transport into Milk
Milk production requires the transport of large amounts of
calcium from the maternal circulation into milk. There is
little paracellular transport in the lactating mammary gland
and calcium must pass through the epithelial cells to enter
the lumen (VanHouten and Wysolmerski, 2007). The plasma
membrane calcium-ATPase 2 (PMCA2), a P-type, ion transport
ATPase pump is expressed on the apical surface of mammary
epithelial cells and transports 60–70% of milk calcium from
the epithelial cells across the apical membrane and into the
acinar lumen (Reinhardt et al., 2004; VanHouten et al., 2007).
The remainder of the calcium in milk appears to be pumped
into the endoplasmic reticulum or secretory granules and to be
secreted bound to caseins via the exocytosis of casein-containing
granules. The CaSR regulates transcellular calcium transport
by altering the activity of PMCA2 in mammary epithelial cells
(VanHouten et al., 2007; VanHouten and Wysolmerski, 2007).
In this instance, delivery of calcium to the mammary gland
activates the CaSR, which, in turn, stimulates PMCA2 activity
and increases calcium transport into milk. The intracellular
signal transduction pathways linking the CaSR to PMCA2
activation are unknown and require further study (VanHouten
and Wysolmerski, 2013). It has been suggested that calcium
enters mammary epithelial cells through interactions between
another calcium pump, SPCA2, and the store-operated calcium
channel, ORAI1 (Cross et al., 2013; Ross et al., 2013). At this
juncture, it is also unknown whether CaSR signaling regulates
this complex to increase calcium entry into the epithelial cells.
However, the available data clearly demonstrate that the CaSR
regulates the amount of calcium transported into milk in a
positive feedback loop that is responsive to the availability of
maternal calcium supplies (VanHouten and Wysolmerski, 2013).
Systemic Aspects of the CaSR-PTHrP and
CaSR-PMCA2 Feedback Loops during Lactation
Current data suggest that the CaSR and PTHrP are involved in
a negative feedback loop that regulates the supply of calcium to
the mammary gland to support milk production (see Figure 1;
VanHouten, 2005; VanHouten and Wysolmerski, 2007, 2013).
The effects of the CaSR on PTHrP production in the lactating
mammary gland mimic the relationship between Ca2+, the
CaSR and PTH production by the parathyroid glands. In
essence, it can be argued that the lactating breast serves as
an accessory parathyroid gland that secretes PTHrP into the
maternal circulation in a calcium-sensitive manner in order to
regulate osteoclastic bone resorption and the release of stored
calcium from the maternal skeleton into the circulation to
be available for uptake by the mammary gland and secretion
into milk. In addition, the CaSR stimulates calcium transport
into milk, allowing the lactating mammary gland to transport
more calcium when it is available and to decrease its calcium
usage when the mother’s supply of calcium becomes limiting.
Ultimately, we believe that this combined control of calcium
mobilization and calcium usage allows the CaSR to fine tune
maternal calcium metabolism to ensure a steady supply of
calcium for milk production but to protect against maternal
hypocalcemia. If calcium is readily available in the diet, more
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FIGURE 1 | The CaSR in normal lactation. Activation of the CaSR in the lactating breast promotes trans-epithelial calcium transport into milk by increasing the
activity of the calcium pump, PMCA2. In addition, activation of the CaSR suppresses PTHrP release into milk and into the systemic circulation. Circulating PTHrP acts
on osteoblasts (Ob) to increase osteoclast (Oc) development and activity through the RANK/RANKL pathway. This, in turn, stimulates bone resorption and liberates
skeletal calcium stores. PTHrP also acts on the kidney to stimulate calcium reabsorption. If serum calcium is decreased, the CaSR decreases calcium transport into
milk to decrease calcium utilization and increases PTHrP secretion into the maternal circulation to increase the supply of calcium from skeletal stores. In this way, the
CaSR helps to maintain a steady supply of calcium for milk production and protects the mother from hypocalcemia if dietary calcium become limiting.
calcium is transported into milk but less PTHrP is produced
and less calcium is liberated from skeletal stores. However,
when dietary calcium is less abundant, the mammary gland
reduces milk calcium content by slowing calcium transport and
more PTHrP is produced, which increases bone resorption and
liberates further calcium from skeletal stores. The importance
of changes in milk PTHrP are less clear. However, recent
studies have demonstrated that milk PTHrP content correlates
inversely with milk calcium content and neonatal calcium
accrual (Mamillapalli et al., 2013). We hypothesize that milk
PTHrP may serve as a metabolic message that entrains maternal
and neonatal bone and calcium metabolism. If less calcium
is available to the mother, she reduces the calcium content
of milk but increases milk PTHrP secretion, which, in turn,
reduces neonatal calcium usage. If calcium is abundant, thenmilk
calcium increases and milk PTHrP decreases, allowing increased
neonatal calcium accrual. While the initial data support this
model, much more work is needed to fully understand how milk
calcium and PTHrP content regulate neonatal calcium and bone
metabolism.
THE CASR IN BREAST CANCER
Breast cancer is a common malignancy in women that has
been estimated to aﬄict one in eight women in the United
States. The American Cancer Society estimates that, in 2016,
249,260 women in the United States will be diagnosed with
breast cancer and approximately 40,890 will die from this
disease (https://cancerstatisticscenter.cancer.org/). A particularly
difficult problem in breast cancer is the frequent occurrence
of bone metastases, which affect up to 65% to 80% of women
with advanced disease (Weilbaecher et al., 2011). The ability
of breast cancer cells to grow in bone has been shown to be
related to their ability to recruit osteoclasts to resorb bone
around the tumor deposit. This causes the release of growth
factors from the bone matrix into the microenvironment around
tumor cells, which increase their proliferation in response.
The increased numbers of tumor cells then stimulate further
osteolysis, which accommodates the growth of the tumor within
the bone and releases even more growth factors to further feed
tumor growth (Chen et al., 2010; Patel et al., 2011; Weilbaecher
et al., 2011). This positive-feedback relationship between breast
cancer cells and bone is referred to as a vicious cycle of osteolysis.
This vicious cycle involves complex interactions between breast
cancer cells, immune cells, osteoblasts and osteoclasts, mediated
by a variety of biochemical signaling pathways and non-
coding RNAs (Keklikoglou et al., 2012; Taipaleenmaki et al.,
2015; Martin, 2016). Investigators have implicated both the
CaSR and PTHrP as among the molecules contributing to
the pathophysiology of osteolytic bone metastases (Yin et al.,
1999; Mihai et al., 2006). In this Section, we will review
current evidence suggesting that the CaSR regulates PTHrP
production and tumor growth in breast cancer as well as
recent findings suggesting that a CaSR-nuclear PTHrP signaling
pathway may contribute to the proliferation and survival of
breast cancer cells in high-calcium environments, such as
bone.
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CaSR Expression in Breast Cancer
Several studies have shown that the CaSR is expressed in
breast carcinomas from patients and in breast cancer cell lines.
CaSR expression was first demonstrated on an mRNA and
protein level in breast tissue samples from 6 different women:
2 samples of normal breast tissue, 2 samples of fibrocystic
disease, and 2 samples of ductal carcinomas (Cheng et al., 1998).
Subsequent reports documented CaSR expression in standard
human breast cancer cell lines, such asMCF-7 andMDA-MB-231
cells (Sanders et al., 2000). Some studies have shown that fully
transformed MCF-7 and MDA-MB-231 breast cancer cell lines
had higher CaSR levels than the nonmalignant breast cell lines,
Hs578Bst and MCF-10A cells (Huang et al., 2009; VanHouten
and Wysolmerski, 2013). In addition, we examined data from
a study of rat mammary tumors induced by the chemical
carcinogen N-Nitroso-N-methylurea (NMU) (Chan et al., 2005)
and found that Casr mRNA levels were significantly higher in
tumors as compared to normal mammary tissue (Kim et al.,
2016). In contrast, recent studies from the Yang laboratory have
suggested that human breast cancers may express lower levels of
CaSR than normal breast tissue (Li et al., 2014a,b). In addition,
they found that the “AG” or “GG” genotype at SNP rs17251221
was associated with reduced CaSR protein levels in 15 tumors
and an increase in the risk of breast cancer in a case-control
study of Chinese patients with (n = 217) or without (n = 231)
breast cancer (Li et al., 2014a). Interestingly this same intronic
polymorphism has been associated with prostate and ovarian
cancer risk as well (Jorde et al., 2013; Jeong et al., 2016). A
different study in 3663 cases and 4687 controls of women of
African American descent did not replicate these associations but
did find that another CaSR SNP (rs112594756) was associated
with estrogen receptor status in breast tumors (Yao et al.,
2016). A study that looked at CaSR immunohistochemistry
in histological sections of primary tumors from 65 patients
with metastatic breast cancer showed that the levels of CaSR
expression varied among the different tumors and that these
differences correlated with the biological behavior of the tumors.
Primary tumors with high levels of CaSR expression were
associated with bone metastases while those with lower levels
of CaSR expression were not (Mihai et al., 2006). Finally, we
examined CaSR protein expression using the semi-automated
immunofluorescence AQUA platform in a tissue microarray
consisting of 652 breast tumors with a median clinical follow
up of 8.9 years (YTMA49) (Camp et al., 2002; VanHouten
et al., 2010). In YTMA49, CaSR levels correlated inversely with
pathological progesterone receptor positive status and positively
with node-positive status. CaSR levels above the median value
were associated with significantly shorter survival than those
below the median, although, when considered as a continuous
variable, CaSR levels did not significantly predict survival (Kim
et al., 2016).
Other than to say that the CaSR is expressed in breast cancers
and that there may be associations between CaSR expression
and different aspects of breast cancer behavior, it is difficult to
synthesize the above data into a coherent picture. One possibility
is that decreased expression of the CaSR may be associated
with an increased risk of developing breast cancer but, once
breast cancer is established, tumor levels of CaSR may alter
behaviors such as the ability to grow in bone. However, the
results from the above case-control studies are based on relatively
small numbers and larger studies will be required to determine
whether increased or decreased levels of CaSR expression alter
breast cancer risk. Furthermore, we did not find that ablation
of the Casr gene in MMTV-PyMT transgenic mice increased
the incidence of mammary tumors (see below) (Kim et al.,
2016). It should also be noted that SNPs in the CASR gene
locus have not been associated with breast cancer risk in GWAS
studies (Fachal and Dunning, 2015). Very little is known about
the regulation of CaSR expression in breast cancer cells and,
therefore, we do not yet understand themechanisms determining
the level of CaSR expression in individual cancers. One study
showed that BRCA1 regulates the expression of CaSR in MCF-
7 and MDA-MB-231 cells but it is not known whether breast
tumors in patients with BRCA1mutations have different levels of
CaSR expression than non-BRCA1-associated tumors (Promkan
et al., 2011). Clearly, given the suggestion that CaSR levels
might influence the likelihood of breast cancer risk, the estrogen-
receptor status of tumors and/or the growth of bone metastasis,
these issues need to be explored in larger studies with sufficient
power to examine the different genetic sub-types of breast cancer
individually.
Function of the CaSR in Breast Cancer
Proliferation and Cell Death
Studies examining the effects of CaSR signaling on proliferation
and cell death in breast cancer cells have reported contradictory
results. A majority of studies have focused on cell proliferation
and different labs have reported opposite results sometimes using
the same cell lines. In one study, Ca2+ concentrations between
1.4 and 5.0 mM stimulated the proliferation of MCF-7 cells
by 25 ± 3% as assessed by measuring cell accumulation (El
Hiani et al., 2009a). These authors described a pathway by which
stimulation of the CaSR activated membrane metalloproteinases
(MMPs), which led to shedding of membrane-bound EGF-
family growth factors, stimulation of the EGFR, ERK1/2
phosphorylation, upregulation of the transient receptor potential
channel 1 (TRPC1) and the stimulation of cell proliferation
(El Hiani et al., 2009b). It has been well documented that
GPCRs can transactivate EGFRs both in ligand-dependent and
ligand-independent signaling pathways (Bhola and Grandis,
2008), and the CaSR has been reported to activate the EGFR
in this manner in leydig cancer cells, fibroblasts, and prostate
cancer cells suggesting that this could be a commonly utilized
signaling mechanism (Yano et al., 2004; Tfelt-Hansen et al.,
2005; Tomlins et al., 2005). Activation of the CaSR in MCF-7
and MDA-MB-231 breast cancer cells has also been shown to
increase the production of phosphocholine and the expression
of choline kinase through activation of Gα12 and Rho (Huang
et al., 2009). Furthermore, overexpression of choline kinase
in MCF-7 breast cancer cell has been shown to increase
their invasiveness and drug resistance (Shah et al., 2010). The
regulation of phosphocholine synthesis seems to be operative in
human tumors in vivo as Baio and colleagues have used MRI
spectroscopy in 23 patients to demonstrate a positive correlation
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between the pre-operative choline content of breast cancers
and the staining intensity of CaSR immunohistochemistry
on pathological specimens after surgery (Baio et al., 2015).
Elevated levels of phosphocholine and total choline-containing
compounds have been observed in almost every cancer type
studied and may be associated with tumor progression (Glunde
et al., 2011). In the aggregate, these data support that notion that
the CaSR promotes increased proliferation of breast cancer cells
and suggest two interesting signaling pathways that may mediate
these effects.
In contrast to the above studies, other reports have suggested
that CaSR signaling has no effect, or reduces proliferation and
decreases the malignant behavior of breast cancer cells (Liu
et al., 2009; Promkan et al., 2011). Sanders et al. examined
responses to varying concentrations of Ca2+ between 0.5 and
10mM and found that changing extracellular calcium had
no effect on cell proliferation in MCF-7 or MDA-MB-231
cells as assessed by cell accumulation (Sanders et al., 2000).
In a different study, Liu and colleagues found that exposing
MCF-7 cells to physiological concentrations of Ca2+ (1.4mM)
reduced proliferation (as assessed by changes in cell numbers)
as compared to low concentrations of Ca2+ (0.175–0.2mM)
(Liu et al., 2009). These investigators have also reported that
activation of the CaSR increased the sensitivity of MCF-7 and
MDA-MB-231 breast cancer cells to cell death in response to
paclitaxel (Liu et al., 2009; Promkan et al., 2011). Similar findings
have been reported in colon cancer, where it has been proposed
that activation of the CaSR inhibits tumor progression and
enhances chemotherapeutic responses (Rogers et al., 2012). The
growth inhibitory effects of the CaSR in breast cancer cells have
been reported to be mediated by the downregulation of the
expression of survivin, a well described anti-apoptotic factor in
breast and other cancers (Liu et al., 2009; Promkan et al., 2011).
Interestingly, in these studies, wild-type BRCA1 was shown
to inhibit survivin expression in a CaSR-dependent manner
(Promkan et al., 2011). Data from these several studies suggest
that the CaSR inhibits proliferation and promotes cell death in
breast cancer cell lines, implying that it may inhibit breast cancer
development and/or progression.
It is unclear how to interpret the contradictory findings
suggesting that the CaSR both opposes and promotes
proliferation and/or cell death, especially when groups reporting
opposite findings have used the same cell lines. In essence, one
can find data showing that high Ca2+ stimulates, inhibits or has
no effect on the proliferation of MCF-7 or MDA-MB-231 cells.
The reported differences might be explained by differences in the
Ca2+ concentration used by the different groups (El Hiani et al.,
2009a,b; Liu et al., 2009; Promkan et al., 2011) or they may be
the consequence of complex patterns of downstream signaling
that might be very context dependent (Mamillapalli et al., 2008;
Promkan et al., 2011; Breitwieser, 2012; Chakravarti et al., 2012).
Regulation of Cell Migration
The development of distant metastases is perhaps the most
significant cause of cancer mortality. Metastasis is a multi-step
process, which requires cells to migrate in order for them to
successfully invade surrounding tissues, to disseminate widely
and to colonize other tissue and form metastases. Several studies
have suggested that the CaSR can promote cell migration and
therefore may promote the development of metastases. Using the
Boyden Chamber and Scratch Wound migration assays, Saidak
et al. showed that stimulation of the CaSR with extracellular
calcium concentrations between 1.8 and 5.0mM stimulated the
migration of MCF7, T47D and MDA-MB-231 breast cancer
cells (Saidak et al., 2009). Interestingly, of these 3 cell lines,
the highly bone metastatic MDA-MB-231 cells showed the
most vigorous cell migration response. Knocking down CaSR
expression inhibited cell migration in response to Ca2+ in all
three, cell lines demonstrating that the CaSR mediated the
migratory effect of extracellular calcium (Saidak et al., 2009).
Activation of the CaSR appeared to enhance migration in these
cells by activating the ERK1/2, MAPK and phospholipase Cβ
(PLCβ) pathways. Activation of the CaSR has also been shown
to induce the secretion of a series of pro-angiogenic cytokines
by MDA-MB-231 cells, at least in part, through activation of
EGFR signaling (Hernandez-Bedolla et al., 2015). In this instance
the CaSR appears to indirectly regulate the migration and
morphogenesis of endothelial cells and may contribute to tumor
neovascularization. The CaSR has also been shown to affect
migration in other cell types. In medullary thyroid carcinoma
cells, the CaSR interacts with β1 integrin, modulating cellular
adhesion and inducing migration, through a PLC/intracellular
calcium-mediated pathway (Tharmalingam et al., 2011). In
keratinocytes, the CaSR physically interacts with Trio, Rho,
and filamin A to form a signaling complex that regulates
E-cadherin-mediated cell-cell adhesion and differentiation (Tu
and You, 2014). Finally, the CaSR also has been shown to
modulate E-cadherin’s membrane localization and binding with
β-catenin in colon carcinoma cells (Wang et al., 2010). In the
aggregate, these findings suggest that the CaSR may regulate
cell migration in breast cancer cells, however, much more work
must be done in this area to determine how important these
observations in vitro are to the behavior of breast cancers
in vivo.
Regulation of PTHrP Production
Activation of the CaSR in normal mammary epithelial cells
reduces PTHrP mRNA expression and PTHrP secretion
(VanHouten et al., 2004; Ardeshirpour et al., 2006; Mamillapalli
et al., 2008; 2013). However, just the opposite has been observed
for breast cancer cells. In immortalized or malignant breast cells,
such as Comma D, MCF-7, BT474 and MDA-MB-231 cells,
activation of the CaSR with Ca2+, spermine, aminoglycoside
antibiotics, or allosteric (type-II) calcimimetics has been shown
to stimulate PTHrP secretion (Sanders et al., 2000; Mamillapalli
et al., 2008; Kim et al., 2016). Interestingly, activation of the CaSR
can act synergistically with TGFβ to increase PTHrP secretion in
hepatocytes as well as MCF-7 and MDA-MB-231 breast cancer
cells, a characteristic that may contribute to the pathogenesis
of bone metastasis (Sanders et al., 2000; Organista-Juarez et al.,
2013). Our laboratory has been interested in understanding the
mechanisms by which malignant transformation of mammary
epithelial cells causes CaSR activation to switch from inhibiting
PTHrP production to stimulating PTHrP production. Initial
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studies demonstrated that divergent cAMP production, but
not alterations in MAPK or PLC signaling correlated with
the changes in PTHrP production (Mamillapalli et al., 2008).
Activation of the CaSR decreases cAMP levels in normal
breast cells, but increases cAMP response in breast cancer cells
(Mamillapalli et al., 2008; Kim et al., 2016). We found that
in normal breast cells, the CaSR couples to Gαi and inhibits
adenylyl cyclase while, in breast cancer cells, the CaSR couples to
Gαs and stimulates cAMP production. The Pthlh gene is known
to be regulated by a cAMP-response element located within
exon 4 of the human gene, and the effects of CaSR activation
on PTHrP production in these different cell types could be
mimicked by manipulating cAMP levels independently from
CaSR activation (Chilco et al., 1998; Mamillapalli et al., 2008).
Therefore, it appears that during the transformation of normal
breast cells into malignant breast cancer cells, the CaSR switches
its G-protein preference, which, in turn, leads to completely
opposite effects on PTHrP production. Ongoing studies are
attempting to define the molecular mechanisms that underlie
the G-protein switching that occurs in response to malignant
transformation.
A CaSR-nuclear PTHrP Pathway Regulates Cell
Proliferation and Survival
Given that the CaSR upregulates PTHrP and given that PTHrP
has been shown to regulate breast cancer progression, we were
interested in determining whether PTHrPmight mediate some of
the effects of the CaSR on breast cancer cells in vitro and in vivo.
In order to examine this question, we first asked whether there
was an association between CaSR and PTHrP levels in breast
cancers. In NMU-induced mammary tumors in rats, there was
a clear positive correlation between Casr and PthlhmRNA levels.
This was also true in human breast cancers at both an mRNA
and protein level; CASR gene expression correlated directly with
PTHLH gene expression in a gene array study of 204 human
breast tumors (Mu et al., 2012; Kim et al., 2016) and CaSR and
PTHrP protein expression showed a positive correlation in the
YTMA49 tissue array of 652 breast tumors discussed previously
(Camp et al., 2002; VanHouten et al., 2010; Kim et al., 2016).
Finally, when we disrupted the Casr gene in mammary tumors
in MMTV-Cre; CaSRlox/lox; MMTV-PyMT mice, tumor PTHrP
mRNA levels were significantly reduced (Kim et al., 2016).
Together, these data demonstrate that activation of the CaSR
increases PTHrP production by breast cancer cells in rodents and
in humans, both in vitro and in vivo.
Next, we found that knocking down either the CaSR or
PTHrP in BT474 cells and MDA-MB-231 cells both inhibited
proliferation and promoted cell death in response to high
extracellular calcium levels. Stimulation of the CaSR promoted
proliferation by reducing p27kip1 levels and increasing CDK2
activity while it promoted cell survival by inhibiting nuclear
accumulation of apoptosis-inducing factor (AIF) (Figure 2). We
also found that knocking out the CaSR inhibited the proliferation
of mammary tumor cells in MMTV-Cre; CaSRlox/lox; MMTV-
PyMT mice in vivo, slowing the growth of tumors. Furthermore,
disrupting the CaSR inhibited growth and increased apoptosis
in MMTV-PyMT tumor cells grown ex vivo, again by altering
FIGURE 2 | The CaSR-nuclear PTHrP pathway. CaSR activation in breast
cancer cells, stimulates PTHrP production through increased intracellular
cAMP levels and also promotes the proliferation and inhibits cell death in high
extracellular calcium concentrations. The effects of the CaSR on tumor cell
growth appear to be mediated by nuclear actions of PTHrP that decrease
expression of the cell cycle inhibitor p27kip1 and that prevent nuclear
accumulation of apoptosis-inducing factor (AIF) which activates apoptotic cell
death.
p27kip1 levels and nuclear AIF accumulation respectively.
Interesting, although disruption of the PTHrP gene mirrored
the effects of targeting the Casr gene, disruption of the Type
1 PTH/PTHrP receptor (PTH1R) did not (Kremer et al., 2011;
Li et al., 2011; Kim et al., 2016). In addition, adding PTHrP to
the media of cells could not rescue the loss of the CaSR, but
transducing the same cells with a viral expression plasmid for
wtPTHrP did rescue both the defects in proliferation and cell
survival. By contrast, transducing the cells with a mutant form of
PTHrP lacking the ability to translocate into the nucleus (1NLS-
PTHrP) did not rescue the phenotytes caused by loss of the
CaSR (Kim et al., 2016). In the aggregate, these findings clearly
suggest that the CaSR affects breast cancer cell proliferation
and apoptosis, at least in part, by stimulating the production of
PTHrP, which, in turn, acts in the nucleus to regulate p27kip1 and
AIF levels (see Figure 3).
Does the CaSR Contribute to Bone
Metastases?
As discussed previously, Mihai et al. (2006) reported that the
levels of tumor CaSR expression predicted the development of
bone metastases. Larger clinical studies are needed to confirm
these findings, but, in light of our recent findings, it is interesting
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FIGURE 3 | The CaSR in breast cancer. In breast cancer cells, stimulation of the CaSR increases PTHrP production. Therefore, the high local calcium
concentrations surrounding bone metastases would be expected to stimulate PTHrP secretion, which would stimulate osteoblasts (Ob) to produce more RANKL,
thereby driving more osteolysis and releasing growth factors (GF) from the bone matrix that stimulate tumor cell growth. As a result, activation of the CaSR facilitates a
feed-forward, vicious cycle of bone resorption, tumor growth and osteolysis. In addition, the CaSR increase the PMCA2 calcium pump activity to protect the breast
cancer cells from calcium-mediated apoptosis, and regulates the TRPC1 calcium channel, which can stimulate proliferation. Finally, as outlined in Figure 2, activation
of the CaSR promotes breast cancer cell proliferation and enhances cell survival by activating a nuclear PTHrP signaling pathway that inhibits p27kip1 and AIF
respectively. These findings suggest that extracellular calcium may promote tumor cell growth by activating the CaSR, which, in turn, can activate PTHrP-dependent
and PTHrP-independent signaling pathways that stimulate cancer cell proliferation, inhibit cancer cell death and promote osteoclastic bone resorption.
to speculate on mechanisms by which the CaSR might promote
the development of osteolytic bone metastases. In order to
metastasize to the bone and grow in size, cancer cells must
resorb the surrounding mineralized tissue, which requires them
to stimulate osteoclast development and/or activity. Accelerated
osteoclastic bone resorption, in turn, releases high levels of Ca2+
into the local microenvironment (Akhtari et al., 2008; Patel et al.,
2011; Theriault and Theriault, 2012). For instance, some studies
suggest that Ca2+ concentrations may increase to levels as high as
40 mM in the microenvironment surrounding actively resorbing
osteoclasts (Silver et al., 1988; Berger et al., 2001). Therefore,
it would be advantageous for a tumor cell to respond to Ca2+
in ways that would stimulate cell growth and further promote
osteolysis. Given that PTHrP stimulates osteoclast differentiation
and activity (Yin et al., 1999; Akhtari et al., 2008; Patel et al.,
2011; Theriault and Theriault, 2012), increased PTHrP secretion
in response to high Ca2+ levels would be expected to act in
a paracrine fashion and contribute to accelerated osteolysis
(Mamillapalli et al., 2008; Figure 3). Our findings also suggest
that CaSR signaling can increase intracrine/nuclear signaling
by PTHrP and directly stimulate tumor cell proliferation and
enhance the ability of the cells to survive in the face of the elevated
extracellular calcium concentrations resulting from active bone
resorption (Figure 3). As discussed previously, increased bone
resorption releases bone matrix-derived growth factors such
as TGF-β, IGFs and FGFs, all of which can stimulate tumor
cell growth and/or increase PTHrP production, defining a
vicious cycle of osteolysis (Chirgwin and Guise, 2000; Mundy,
2002; Kremer et al., 2011). The majority of breast cancers that
metastasize to bone are estrogen receptor (ER)-positive so it is
also interesting that activation of the CaSR has been shown to
increase ER transcriptional activity and enhance the effects of
estradiol in MCF-7 cells (Journe et al., 2004; Leclercq, 2012).
All of these observations demonstrate that CaSR signaling can
exert proliferative, pro-survival and bone-resorbing activities
that would be expected to enhance the progression of bone
metastases (Figure 3). Therefore, although much research will be
required to validate the above hypothesis, the CaSR-PTHrP axis
may present new therapeutic opportunities to develop treatments
for bone metastases from breast cancers.
CONCLUSIONS
The CaSR has a central role in orchestrating systemic calcium
homeostasis. However, it is also expressed in a variety of
different organs such as the breast, where it may contribute
to the regulation of cell proliferation, cell differentiation and
cell migration in response to alterations in the extracellular
environment. By regulating PTHrP production in the lactating
mammary gland, the CaSR allows mammary epithelial cells to
actively participate in reordering systemic calcium and bone
metabolism to provide calcium for milk production. In a similar
fashion, the CaSR appears to regulate PTHrP production by
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breast cancer cells, which causes osteolysis and stimulates the
growth of tumor cells, contributing to the pathophysiology of
osteolytic bone metastases. It is unlikely that PTHrP mediates
all of the effects of the CaSR on breast cancers but, at this
point, relatively little is known about the direct effects of CaSR
signaling on breast cancer cell behavior, and many of the initial
observation have been contradictory. Thus, more work will be
required to fully elucidate the role of the CaSR in both normal
and malignant breast cells and to determine whether targeting
the CaSR-PTHrP axis would be an effective strategy against breast
cancers.
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